INmune Bio posts $24.5M net loss, CEO replaced; INKmune trial meets endpoints

Inmune Bio, Inc.

Net loss $24.5M in Q2 2025 vs $9.7M in Q2 2024; includes $16.5M impairment of in-process R&D intangibles.
CEO RJ Tesi retires; David Moss appointed President & CEO; Cory Ellspermann Interim CFO.
INKmune CaRe PC trial in mCRPC met primary safety and secondary endpoints; trial closed to enrollment.
XPro MINDFuL trial missed primary cognitive endpoints overall; positive trends in enriched biomarker subset.
Cash $33.4M as of June 30; completed $19M registered direct offering.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.